AI models need more data about biology, and OpenAI is paying to create it
Last year Ruxandra Teslo, a policy analyst who focuses on clinical trials, posted an idea for supercharging medical AI systems: Use data from failed biotech companies. By bidding at their bankruptcy proceedings, she proposed, it might be possible to obtain detailed regulatory filings, manufacturing strategies, and safety data—types of information usually considered trade secrets. She…
Summary as supplied by MIT Technology Review. This page indexes the story — the reporting itself lives at the publisher.
Read the original at MIT Technology Review technologyreview.com
Recorded as negative coverage
Lexicon match on “bankruptcy”, “failed”.
Rage Against the Clock does not endorse or oppose the stories it tracks. Sentiment labels describe the tone of the coverage toward its subject, not whether the reporting is accurate or whether we agree with it.